BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MannKind (MNKD)MannKindEarnings

Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza ® pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow ™

Related news

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

BLTEBelite Bio2026-05-20 10:00 EST

Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

ALTAltimmune2026-05-13 11:30 EST

Altimmune Announces First Quarter 2026 Financial Results and Business Update

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

SGMTSagimet Biosciences2026-05-12 11:30 EST

Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

ALGSAligos Therapeutics2026-05-07 20:06 EST

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

LXRXLexicon Pharmaceuticals2026-05-07 11:30 EST

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MNKDMannKind2026-07-24 10:35 EST

MannKind Announces $50 Million Private Placement

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Stock data

Close
3.89 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States